AbCellera Biologics Inc.
ABCL
$10.97
$0.625.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -55.43M | -43.17M | -8.95M | -57.12M | -34.73M |
| Total Depreciation and Amortization | 8.78M | 8.66M | 7.92M | 7.24M | 7.06M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.93M | 14.39M | 12.50M | 15.43M | 12.06M |
| Change in Net Operating Assets | 55.64M | -13.40M | -46.22M | -18.14M | -16.80M |
| Cash from Operations | 25.92M | -33.52M | -34.74M | -52.59M | -32.40M |
| Capital Expenditure | -2.13M | -3.83M | -9.84M | -8.93M | -13.37M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.47M | -21.25M | 84.98M | 45.42M | -18.45M |
| Cash from Investing | 11.34M | -25.08M | 75.14M | 36.49M | -31.81M |
| Total Debt Issued | -7.19M | 7.19M | 10.52M | 7.55M | -5.97M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 13.59M | -- | -6.41M | -182.00K | 2.60M |
| Cash from Financing | 6.39M | 7.19M | 4.12M | 7.37M | -3.38M |
| Foreign Exchange rate Adjustments | -430.00K | -38.00K | 290.00K | -544.00K | 761.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 43.23M | -51.45M | 44.80M | -9.28M | -66.83M |